人物紹介
武井佳史（たけいよしふみ）は、医学・薬学の研究者です。
長年にわたり、医学・薬学分野において研究と教育に従事しています。
経歴
武井佳史は、1991年に岐阜薬科大学を卒業され、1993年には同大学大学院薬学研究科にて博士前期課程を修了されています。
その後、1999年にマルコ製薬株式会社の創薬研究所で研究員として勤務された後、名古屋大学大学院医学系研究科に進学されました。
2002年には同研究科を修了し、同年から名古屋大学大学院医学系研究科において教育と研究に従事されています。
2016年以降は、愛知学院大学薬学部にて教育と研究活動を続けられており、長年にわたり薬学分野の発展に貢献されています。
取得特許一覧
以下に、武井佳史が取得した特許についてまとめました。
・武井佳史、藤島達也、村松喬、門松健治
「エレクトロポレーション装置の制御方法」
特許番号：第5176104号（2013年1月18日登録、日本）
国際出願番号：PCT/JP/2006/314059
・山本徳則、小出直史、後藤百万、武井佳史
「脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤」
特許番号：第5035737号（2012年7月13日登録、日本）
国際出願番号：PCT/JP/2010/071633
・山本徳則、小出直史、武井佳史、松川宣久、舟橋康人、後藤百万
「脂肪組織由来間葉系幹細胞を含有する、勃起不全又は尿意障害用の細胞製剤」
特許番号：第4953335号（2012年3月23日登録、日本）
国際出願番号：PCT/JP/2010/065271
米国特許取得：US 8,808,688（2014年8月19日）
・武井佳史、門松健治、村松喬
「siRNAを用いたヒト血管内皮増殖因子の発現の強い抑制」
特許番号：第4480125号（2010年3月26日登録、日本）
・武井佳史、門松健治、村松喬
「アンチセンスオリゴヌクレオチドの新規作成法」
特許番号：第4048296号（2007年12月7日登録、日本）
・勝崎智之、武井佳史、屋鋪哲也、舟岡宏幸、白井晶、大軽靖彦、賀登志朗、石井泰雄
「スルトプリド誘導体及び抗スルトプリド抗体」
特許番号：第3408158号（2003年3月14日登録、日本）
論文業績
以下に、武井佳史の論文業績についてまとめました。
1.Takei Y, Kurobe M, Uchida A, Hayashi K. Serum concentration of basic fibroblast growth factor in breast cancer. Clin Chem, 40:1980-1981 (1994). Imact factor 7.1
2. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y. Modification of b2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int, 49:861-867 (1996). Imact factor 14.8
3. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid b2-microglobulin is modified with Ne-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int, 50:1303-1309 (1996). Imact factor 14.8
4. Takei Y, Higashira H, Yamamoto T, Hayashi K. Mitogenic activity toward human breast cancer cell line MCF-7 of two bFGFs purified from sera of breast cancer patients: co-operative role of cathepsin D. Br Cancer Res Tr 43:53-63 (1997).
5. Niwa T, Katsuzaki T, Ishizaki Y, Hayase F, Miyazaki T, Uematsu T, Tatemichi N, Takei Y. Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes. FEBS Lett, 407:297-302 (1997).
6. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest, 99:1272-1280 (1997). Imact factor 13.3
7. Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y. Amyloid b2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int,51:187-194 (1997). Imact factor 14.8
8. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T. Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res, 61:8486-8491 (2001). Imact factor 12.5
9. Takei Y, Kadomatsu K, Itoh H, Sato W, Nakazawa K, Kubota S, Muramatsu T. 5’-, 3’-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine: its design and application for cancer therapy. J Biol Chem, 277:23800-23806 (2002).
10. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. , corresponding author.
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res, 64:3365-3370 (2004). Imact factor 12.5
11. Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T. , corresponding author.
Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer, 114:490-497 (2005).
12. Sato W, Takei Y, Yuzawa Y, Matsuo S, Kadomatsu K, Muramatsu T. Midkine antisense oligodeoxynucleotide inhibits renal damage induced by ischemic reperfusion. Kidney Int, 67:1330-1339 (2005). Imact factor 14.8
13. Takei Y, Kadomatsu K, Goto T, Muramatsu T. , corresponding author. Combinational antitumor effect of siRNA as to midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer, 107:864-873 (2006).
14. Takei Y, Nemoto T, Mu P, Fujishima F, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K. , corresponding author. In vivo silencing of a molecular target by short interfering RNA electroporation: Tumor vascularization correlates to delivery efficiency. Mol Cancer Ther, 7:211-221 (2008).
15. Ishimoto T, Takei Y, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K. , corresponding author. Downregulation of monocyte chemoattractant protein-1involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol Ther, 16:387-95 (2008). Imact factor 12.1
16. Sakamoto I, Ito Y, Mizuno M, Suzuki Y, Sawai A, Tanaka A, Maruyama S, Takei Y, Yuzawa Y, Matsuo S. Lymphatic vessels develop in tubulo-interstitial fibrosis. Kidney Int, 75:828-838 (2009). Imact factor 14.8
17. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu, K, Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer, 125:2978-2990 (2009).
18. Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G, Saitou M, Takigami I, Matsuhashi A, Yamada K, Takei Y. EWS/Fli-1 chimeric fusion gene up-regulates vascular endothelial growth factor-A. Int J Cancer, 126:2790-2798 (2010).
19. Takei Y, Takigahira M, Mihara K, Tarumi Y, Yanagihara K. , corresponding author.
The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res, 71:1442-1453 (2011). Imact factor 12.5
20. Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, Asaoku H, Takihara Y, Kimura A. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia, 26:365-367 (2012).
21. Inaba S, Nagahara S, Makita N, Tarumi Y, Ishimoto T, Matsuo S, Kadomatsu K, Takei Y. Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther, 20:356-366 (2012). Imact factor 12.1
22. Suzuki Y, Ito Y, Mizuno M, Kinashi H, Sawai A, Noda Y, Mizuno T, Shimizu H, Fujita Y, Matsui K, Maruyama S, Imai E, Matsuo S, Takei Y. Transforming growth factor-β induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction. Kidney Int, 81:865-879 (2012). Imact factor 14.8
23. Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, Hattori R, Matsukawa Y, Mizuno T, Noda Y, Nishimura H, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y. TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol, 24:1627-1642 (2013).
24. Takei Y. Electroporation-mediated siRNA delivery into tumors. Methods Mol Biol, 1121: 131-138 (2014).
25. Takei Y, Ohnishi N, Kisaka M, Mihara K. , corresponding author. Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas. SpringerPlus, 3: 288 (2014).
26. Yuan Y, Makita N, Cao D, Mihara K, Kadomatsu K, Takei Y. Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice, and its anticancer effects.
Nucleic Acid Ther, 25: 85-94 (2015).
27. Terabayashi T, Ito Y, Mizuno M, Suzuki Y, Kinashi H, Sakata F, Tomita T, Iguchi D, Tawada M, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y. Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury. Lab Invest, 95: 1029-1043 (2015).
28. Tawada M, Ito Y, Hamada C, Honda K, Mizuno M, Suzuki Y, Sakata F, Terabayashi T, Matsukawa Y, Maruyama S, Imai E, Matsuo S, Takei Y. Vascular endothelial cell injury is an important factor in the development of encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients. PLoS One, 11: e0154644 (2016).
29. Sakata F, Ito Y, Mizuno M, Sawai A, Suzuki Y, Tomita T, Tawada M, Tanaka A, Hirayama A, Sagara A, Wada T, Maruyama S, Soga T, Matsuo S, Imai E, Takei Y. Sodium chloride promotes tissue inflammation via osmotic stimuli in sub-total-nephrectomized mice. Lab Invest, 97: 432-446 (2017).
30. Takei Y, Shen G, Morita-Kondo A, Hara T, Mihara K, Yanagihara K.
, corresponding author. MicroRNAs regulating epithelial-mesenchymal transition can be targeted to inhibit peritoneal dissemination in human scirrhous gastric cancers.
Pathobiology, 85: 232-246 (2018).
31. Kinashi H, Ito Y, Sun T, Katsuno T, Takei Y. Roles of the TGF-β–VEGF-C pathway in fibrosis-related lymphangiogenesis. Int J Mol Sci, 19: 2487 (2018).
32. Takei Y. siRNA-based medicine targeting human bcl-xL against cancers. Methods in Mol Biol, 1974: 31-40 (2019).
33. Takei Y, Hara T, Suzuki A, Mihara K, Yanagihara K. , corresponding author.
Long non-coding RNA HOTAIR promotes epithelial-mesenchymal transition and is a suitable target to inhibit peritoneal dissemination in human scirrhous gastric cancers.
Pathobiology, 87: 277-290 (2020).
34. Yamamoto T, Gotoh M, Koide N, Funahashi Y, Shimizu S, Takei Y. Influence of human adipose stem cells on prostate cancer cell growth. Nagoya J Med Sci, 82: 217-224 (2020).
35. Hara T, Nomura Y, Hattori M, Mihara K, Yanagihara K, Takei Y. Elevated expression of CELSR1 is associated with peritoneal metastasis in human scirrhous gastric cancers. BPB Reports, 4: 103-111 (2021).
36. Hara T, Tominaga Y, Ueda K, Mihara K, Yanagihara K, Takei Y. Elevated METTL9 is associated with peritoneal dissemination in human scirrhous gastric cancers.
Biochemistry and Biophysics Reports, 30: 101255 (2022).
